Developer docs
API playgroundTry for free, no card

Search company profiles

Biocomposites

Full company profile

uuid0006pe8

Namestring
Biocomposites
Legal namestring
Biocomposites Ltd.
Company typeenum
Private
Founded yearint
1993
Descriptiontext

Biocomposites Ltd. is an international medical device company founded in 1993 and headquartered at Keele's Science and Innovation Park in the United Kingdom. The company engineers, manufactures, and commercializes calcium compound medical devices focused on two clinical domains: bone regeneration and musculoskeletal infection management. Its portfolio spans absorbable calcium sulfate antibiotic carriers (STIMULAN), acrylic bone cements and preformed antibiotic-loaded spacers for joint revision (SYNICEM), nanocrystalline hydroxyapatite bone graft substitutes (NanoBone), biphasic tricalcium phosphate composites (genex, Allogran-R), bone cements (Subiton), and synthetic calcium composite interference screws (Biosteon, Bilok) for sports medicine applications.

The company's underlying technology is anchored by proprietary materials science, notably the DRy26 recrystallization process—a 26-step, 6-week pharmaceutical-grade calcium sulfate synthesis—and NanoBone's unsintered nanocrystalline hydroxyapatite embedded in a silica gel matrix. These are protected by an extensive patent portfolio across the US, EU, China, and Japan. STIMULAN holds regulatory distinction as the only calcium matrix antibiotic carrier certified under EU MDR for mixing with combinations of Gram-positive and Gram-negative antibiotics, sustaining elution above minimum inhibitory concentration for over 40 days.

Biocomposites operates a hybrid direct-sales and distributor go-to-market model, reaching healthcare providers in 100+ countries, with products used in over one million procedures annually. The company maintains manufacturing in Keele (UK) and Chamberet, France (via its Synimed subsidiary acquired in 2022), produces approximately one million units per year, and is privately held with growth-equity backing from TA Associates and Novo Holdings following a March 2025 investment. Biosteon products are distributed exclusively through Stryker for ACL reconstruction. The company's end customers are orthopaedic surgeons, trauma specialists, podiatrists, spine surgeons, and infection management professionals operating in hospital and surgical settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersKeele, United Kingdom
HQ citystring
Keele
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
calcium compound medical devices, bone graft substitutes, antibiotic loaded cements, orthopaedic infection management, calcium sulfate carriers
Industry6 codes
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAA
Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAF
Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Orthopaedic and trauma medical devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Sale of calcium compound medical devices including bone grafts, antibiotic carriers, bone cements, spacers, and interference screws for orthopaedic, trauma, spine, and infection management applications. Products sold through direct sales and distributor network in over 100 countries.

biocomposites.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1STIMULAN
Description

Truly absorbable calcium sulfate antibiotic carrier approved for use in bone and soft tissue. The only calcium matrix antibiotic carrier certified for use in bone and surrounding soft tissue, with products including Rapid Cure and Kit variants.

biocomposites.com
+7 more records
Core offering1 text field

Biocomposites engineers, manufactures, and markets calcium compound and specialty polymer medical devices for bone regeneration and infection management. Its portfolio includes absorbable calcium sulfate antibiotic carriers (STIMULAN), acrylic bone cements and preformed antibiotic-loaded spacers (SYNICEM), nanostructured hydroxyapatite bone graft substitutes (NanoBone), biphasic and beta-tricalcium phosphate bone grafts (genex, Allogran-R), and synthetic calcium composite interference screws (Biosteon, Bilok) used in musculoskeletal infection, trauma, spine, foot and ankle, and sports medicine procedures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • STIMULAN sustains antibiotic levels above MIC for over 40 days
+2 more records
Product overview1 text field

Biocomposites is an international medical device company offering a comprehensive portfolio of calcium compound and specialty polymer medical devices for bone regeneration and infection management. The portfolio includes: STIMULAN® (absorbable calcium sulfate antibiotic carriers), SYNICEM™ (bone cements, spacers, and related surgical products from subsidiary Synimed), NanoBone® (nanostructured hydroxyapatite bone graft), genex® (tricalcium phosphate bone graft), Allogran-R® (β-calcium phosphate substitute), Subiton cements, Biosteon® and Bilok® (interference screws for sports medicine). Products serve musculoskeletal infection, trauma, spine, foot and ankle, and sports injuries specialties across more than 100 countries.

Product and service8 records
1STIMULAN
CategoryAntibiotic carrier
Description

Truly absorbable calcium sulfate antibiotic carrier approved for use in bone and soft tissue for musculoskeletal infection management, including STIMULAN Rapid Cure (3cc/5cc/10cc/20cc bead kits with ~4 minute set time) and STIMULAN Kit (5cc/10cc fully injectable paste with ~8 minute set time), supported by STIMULAN Bullet Mat and Introducer accessories for hard-to-reach defects. Used by orthopaedic surgeons, infection specialists, foot and ankle surgeons, trauma surgeons, and microbiologists for osteomyelitis, periprosthetic joint infections, diabetic foot osteomyelitis, infected non-unions, and surgical site infections.

2SYNICEM
CategoryBone cements and infection management devices
Description

Pioneering product line for infection management encompassing bone cements (SYNICEM 1, SYNICEM 1G with gentamicin, SYNICEM 3, SYNICEM 3G with gentamicin), preformed antibiotic-loaded hip, knee and shoulder spacers with gentamicin for revision procedures, antibiotic-coated intra-medullary CLOUS nails for infected diaphyseal fractures, SYNICEM VTP and SYNICEM KYP cements for vertebroplasty and kyphoplasty, SYNICEM Cranioplastie for cranial and facial reconstruction, and SYNIMIX V vacuum mixing and SERINGUE SYNICEM GUN delivery systems. Manufactured by subsidiary Synimed and distributed through Biocomposites for orthopaedic, neurosurgical, maxillofacial and plastic surgical applications in over 70 countries.

3NanoBone
CategorySynthetic bone graft substitute
Description

Next generation fully synthetic bone graft substitute consisting of nanostructured hydroxyapatite embedded in a silica gel matrix suspended in hydrogel/polymer silica carrier, with unsintered HA preserving a highly porous nanoarchitecture for bone regeneration. Offered as SBX Putty and QD formulations for orthopaedic and trauma surgeons treating bone defects with rapid absorption and reliable bone fusion.

4genex
CategorySynthetic bone graft substitute
Description

Biphasic composite bone graft substitute of beta-tricalcium phosphate and calcium sulfate hemihydrate that acts as a catalyst for bone healing, completely absorbed within 12 months leaving no foreign artifacts, with negatively charged surface chemistry and compressive strength similar to trabecular bone. Available as setting paste, ds paste, and putty formulations for orthopaedic, trauma, spine, and non-union procedures.

5Allogran-R
CategorySynthetic bone graft substitute
Description

Fully absorbable beta tri-calcium phosphate bone substitute with engineered porosity for complete absorption within 6 to 12 months, used as an osteoconductive matrix for treatment of trauma, spine, and non-unions with no risk of disease transmission.

6Subiton Cements
CategoryBone cement
Description

Bone cements optimised for secure and stable fixation in joint replacement surgery, including Subiton RO with high performance mechanical properties, Subiton G with gentamicin for high-risk infection patients, and Subiton GUN and GUN G delivery variants.

7Biosteon
CategoryInterference screws and suture anchors
Description

Synthetic calcium composite interference screws using osteoconductive calcium hydroxyapatite particles in a poly-L-lactic acid (PLLA) matrix, with improved strength retention, bone-bonding potential and pH buffering, alongside the Biosteon IntraLine suture anchor for rotator cuff repairs. Designed for sports medicine surgeons treating ACL injuries and rotator cuff tears where bioresorbable implants are preferred over metal hardware. Distributed exclusively through Stryker.

8Bilok
CategoryInterference screws and suture anchors
Description

Synthetic calcium composite interference screws using beta tri-calcium phosphate particles in a poly-L-lactic acid matrix for ACL and posterior ligament reconstruction, and suture anchors for rotator cuff repairs. Indicated for sports medicine procedures where absorbable implants are preferred.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Artoss GmbH
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-01
Description

Acquired by Biocomposites in June 2023, Artoss GmbH was a German manufacturer of bone graft substitutes using NanoBone technology. The acquisition expanded Biocomposites' product portfolio and global distribution network with proprietary nanocrystalline hydroxyapatite and silica gel technology.

prnewswire.com
2Synimed
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-01-01
Description

Synimed became part of the Biocomposites Group in 2022, bringing the SYNICEM product range including bone cements, spacers, antibiotic-loaded nails, and mixing/delivery systems. Synimed manufactures products at Chamberet, France facility.

biocomposites.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Biosteon interference screws for ACL reconstruction and Biosteon IntraLine Suture Anchor are manufactured by Biocomposites but sold and distributed exclusively through Stryker.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Heraeus Medical is the global leader in orthopaedic bone cements (PALACOS, COPAL) and antibiotic-loaded bone cements, directly comparable to Biocomposites' SYNICEM bone cement and STIMULAN antibiotic carrier franchise for musculoskeletal infection management.

TypeBroad incumbent
Description

Zimmer Biomet is a major orthopaedic device manufacturer with overlapping bone graft, bone substitute, and joint reconstruction portfolios; comparable to Biocomposites' calcium-based bone grafts and SYNICEM spacers used in joint revision.

TypeBroad incumbent
Description

DePuy Synthes is the orthopaedic and trauma division of J&J MedTech, with broad bone graft substitute offerings and trauma plating/nailing systems that overlap with Biocomposites' Allogran-R, NanoBone, and SYNICEM antibiotic-loaded nail products.

TypeBroad incumbent
Description

Stryker is both Biocomposites' exclusive distribution partner for Biosteon ACL/rotator cuff screws and a broad orthopaedic and sports medicine incumbent with overlapping sports medicine and orthobiologic product lines.

TypeBroad incumbent
Description

Smith+Nephew is a global medical device company with significant orthopaedic reconstruction, sports medicine, and advanced wound management portfolios, competing in adjacent segments to Biocomposites' bone grafts and infection-management products.

TypeBroad incumbent
Description

Arthrex is a leading privately-held sports medicine and orthopaedic soft tissue repair company; comparable to Biocomposites' Biosteon/Bilok interference screws and suture anchors for ACL and rotator cuff repair.

TypeEmerging player
Description

Bone Solutions Inc. develops Mg-based and calcium-based bone void fillers and orthobiologics (OSTEOAMP, OSTEOMATRIX), an emerging competitor with similar synthetic bone graft technology to Biocomposites' genex and NanoBone lines.

TypeEmerging player
Description

OsteoRemedies specializes in antibiotic-loaded calcium sulfate bone void fillers and infection management products in orthopaedics, making it a direct niche competitor to Biocomposites' STIMULAN platform.

TypeDirect peer
Description

BONESUPPORT is a Swedish orthobiologics company developing CERAMENT antibiotic-loaded bone void fillers, a direct competitor to Biocomposites' STIMULAN calcium matrix antibiotic carrier for musculoskeletal infection.

TypeBroad incumbent
Description

Medtronic's Spine division offers INFUSE (rhBMP-2) and other orthobiologics used in spinal fusion and bone grafting, comparable to Biocomposites' NanoBone, genex, and Allogran-R products serving spine surgeons.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biocomposites

Orthopaedic and trauma medical devicesbiocomposites.com

What Biocomposites does

Biocomposites Ltd. is an international medical device company founded in 1993 and headquartered at Keele's Science and Innovation Park in the United Kingdom. The company engineers, manufactures, and commercializes calcium compound medical devices focused on two clinical domains: bone regeneration and musculoskeletal infection management. Its portfolio spans absorbable calcium sulfate antibiotic carriers (STIMULAN), acrylic bone cements and preformed antibiotic-loaded spacers for joint revision (SYNICEM), nanocrystalline hydroxyapatite bone graft substitutes (NanoBone), biphasic tricalcium phosphate composites (genex, Allogran-R), bone cements (Subiton), and synthetic calcium composite interference screws (Biosteon, Bilok) for sports medicine applications.

The company's underlying technology is anchored by proprietary materials science, notably the DRy26 recrystallization process—a 26-step, 6-week pharmaceutical-grade calcium sulfate synthesis—and NanoBone's unsintered nanocrystalline hydroxyapatite embedded in a silica gel matrix. These are protected by an extensive patent portfolio across the US, EU, China, and Japan. STIMULAN holds regulatory distinction as the only calcium matrix antibiotic carrier certified under EU MDR for mixing with combinations of Gram-positive and Gram-negative antibiotics, sustaining elution above minimum inhibitory concentration for over 40 days.

Biocomposites operates a hybrid direct-sales and distributor go-to-market model, reaching healthcare providers in 100+ countries, with products used in over one million procedures annually. The company maintains manufacturing in Keele (UK) and Chamberet, France (via its Synimed subsidiary acquired in 2022), produces approximately one million units per year, and is privately held with growth-equity backing from TA Associates and Novo Holdings following a March 2025 investment. Biosteon products are distributed exclusively through Stryker for ACL reconstruction. The company's end customers are orthopaedic surgeons, trauma specialists, podiatrists, spine surgeons, and infection management professionals operating in hospital and surgical settings.

Biocomposites firmographics

Firmographics
Name
Biocomposites
Legal name
Biocomposites Ltd.
Website
https://biocomposites.com
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

Biocomposites industry classification

Industry
Product category
Orthopaedic and trauma medical devices
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAA
Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAHAEAF
Sports Medicine & Soft Tissue Repair Implants (Anchors/Grafts/Meniscal Repair)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Calcium compound medical devices
  • Bone graft substitutes
  • Antibiotic loaded cements
  • Orthopaedic infection management
  • Calcium sulfate carriers

Where Biocomposites is headquartered

Location

Headquarters

HQ city
Keele
HQ country
United Kingdom
HQ region
Europe

Offices9 records

Markets served

Biocomposites business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Sale of calcium compound medical devices including bone grafts, antibiotic carriers, bone cements, spacers, and interference screws for orthopaedic, trauma, spine, and infection management applications. Products sold through direct sales and distributor network in over 100 countries.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Biocomposites product offering

Product offering

Core offering

Biocomposites engineers, manufactures, and markets calcium compound and specialty polymer medical devices for bone regeneration and infection management. Its portfolio includes absorbable calcium sulfate antibiotic carriers (STIMULAN), acrylic bone cements and preformed antibiotic-loaded spacers (SYNICEM), nanostructured hydroxyapatite bone graft substitutes (NanoBone), biphasic and beta-tricalcium phosphate bone grafts (genex, Allogran-R), and synthetic calcium composite interference screws (Biosteon, Bilok) used in musculoskeletal infection, trauma, spine, foot and ankle, and sports medicine procedures.

Product overview

Biocomposites is an international medical device company offering a comprehensive portfolio of calcium compound and specialty polymer medical devices for bone regeneration and infection management. The portfolio includes: STIMULAN® (absorbable calcium sulfate antibiotic carriers), SYNICEM™ (bone cements, spacers, and related surgical products from subsidiary Synimed), NanoBone® (nanostructured hydroxyapatite bone graft), genex® (tricalcium phosphate bone graft), Allogran-R® (β-calcium phosphate substitute), Subiton cements, Biosteon® and Bilok® (interference screws for sports medicine). Products serve musculoskeletal infection, trauma, spine, foot and ankle, and sports injuries specialties across more than 100 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • STIMULAN: Truly absorbable calcium sulfate antibiotic carrier approved for use in bone and soft tissue. The only calcium matrix antibiotic carrier certified for use in bone and surrounding soft tissue, with products including Rapid Cure and Kit variants.
  • SYNICEM
  • NanoBone
  • genex
  • Allogran-R
  • Subiton
  • Biosteon
  • Bilok

Products and services

  • STIMULAN Truly absorbable calcium sulfate antibiotic carrier approved for use in bone and soft tissue for musculoskeletal infection management, including STIMULAN Rapid Cure (3cc/5cc/10cc/20cc bead kits with ~4 minute set time) and STIMULAN Kit (5cc/10cc fully injectable paste with ~8 minute set time), supported by STIMULAN Bullet Mat and Introducer accessories for hard-to-reach defects. Used by orthopaedic surgeons, infection specialists, foot and ankle surgeons, trauma surgeons, and microbiologists for osteomyelitis, periprosthetic joint infections, diabetic foot osteomyelitis, infected non-unions, and surgical site infections.
  • SYNICEM Pioneering product line for infection management encompassing bone cements (SYNICEM 1, SYNICEM 1G with gentamicin, SYNICEM 3, SYNICEM 3G with gentamicin), preformed antibiotic-loaded hip, knee and shoulder spacers with gentamicin for revision procedures, antibiotic-coated intra-medullary CLOUS nails for infected diaphyseal fractures, SYNICEM VTP and SYNICEM KYP cements for vertebroplasty and kyphoplasty, SYNICEM Cranioplastie for cranial and facial reconstruction, and SYNIMIX V vacuum mixing and SERINGUE SYNICEM GUN delivery systems. Manufactured by subsidiary Synimed and distributed through Biocomposites for orthopaedic, neurosurgical, maxillofacial and plastic surgical applications in over 70 countries.
  • NanoBone Next generation fully synthetic bone graft substitute consisting of nanostructured hydroxyapatite embedded in a silica gel matrix suspended in hydrogel/polymer silica carrier, with unsintered HA preserving a highly porous nanoarchitecture for bone regeneration. Offered as SBX Putty and QD formulations for orthopaedic and trauma surgeons treating bone defects with rapid absorption and reliable bone fusion.
  • genex Biphasic composite bone graft substitute of beta-tricalcium phosphate and calcium sulfate hemihydrate that acts as a catalyst for bone healing, completely absorbed within 12 months leaving no foreign artifacts, with negatively charged surface chemistry and compressive strength similar to trabecular bone. Available as setting paste, ds paste, and putty formulations for orthopaedic, trauma, spine, and non-union procedures.
  • Allogran-R Fully absorbable beta tri-calcium phosphate bone substitute with engineered porosity for complete absorption within 6 to 12 months, used as an osteoconductive matrix for treatment of trauma, spine, and non-unions with no risk of disease transmission.
  • Subiton Cements Bone cements optimised for secure and stable fixation in joint replacement surgery, including Subiton RO with high performance mechanical properties, Subiton G with gentamicin for high-risk infection patients, and Subiton GUN and GUN G delivery variants.
  • Biosteon Synthetic calcium composite interference screws using osteoconductive calcium hydroxyapatite particles in a poly-L-lactic acid (PLLA) matrix, with improved strength retention, bone-bonding potential and pH buffering, alongside the Biosteon IntraLine suture anchor for rotator cuff repairs. Designed for sports medicine surgeons treating ACL injuries and rotator cuff tears where bioresorbable implants are preferred over metal hardware. Distributed exclusively through Stryker.
  • Bilok Synthetic calcium composite interference screws using beta tri-calcium phosphate particles in a poly-L-lactic acid matrix for ACL and posterior ligament reconstruction, and suture anchors for rotator cuff repairs. Indicated for sports medicine procedures where absorbable implants are preferred.

Quantifiable outcome

  • STIMULAN sustains antibiotic levels above MIC for over 40 days
  • +2 more outcomes

Companies that use Biocomposites

Customer profile

Segments5 records

Ideal customer profiles2 records

Biocomposites technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Biocomposites partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Artoss GmbHcoreStrategic or Co-development Partner · 1 June 2023Acquired by Biocomposites in June 2023, Artoss GmbH was a German manufacturer of bone graft substitutes using NanoBone technology. The acquisition expanded Biocomposites' product portfolio and global distribution network with proprietary nanocrystalline hydroxyapatite and silica gel technology.
  • SynimedcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2022Synimed became part of the Biocomposites Group in 2022, bringing the SYNICEM product range including bone cements, spacers, antibiotic-loaded nails, and mixing/delivery systems. Synimed manufactures products at Chamberet, France facility.
  • StrykercoreChannel Partner/ Reseller/ DistributorBiosteon interference screws for ACL reconstruction and Biosteon IntraLine Suture Anchor are manufactured by Biocomposites but sold and distributed exclusively through Stryker.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Biocomposites competitors and assessment

Company assessment

Direct peers

  • Heraeus Medical: Heraeus Medical is the global leader in orthopaedic bone cements (PALACOS, COPAL) and antibiotic-loaded bone cements, directly comparable to Biocomposites' SYNICEM bone cement and STIMULAN antibiotic carrier franchise for musculoskeletal infection management.
  • BONESUPPORT Holding AB: BONESUPPORT is a Swedish orthobiologics company developing CERAMENT antibiotic-loaded bone void fillers, a direct competitor to Biocomposites' STIMULAN calcium matrix antibiotic carrier for musculoskeletal infection.

Broad incumbents

  • Zimmer Biomet: Zimmer Biomet is a major orthopaedic device manufacturer with overlapping bone graft, bone substitute, and joint reconstruction portfolios; comparable to Biocomposites' calcium-based bone grafts and SYNICEM spacers used in joint revision.
  • DePuy Synthes (Johnson & Johnson): DePuy Synthes is the orthopaedic and trauma division of J&J MedTech, with broad bone graft substitute offerings and trauma plating/nailing systems that overlap with Biocomposites' Allogran-R, NanoBone, and SYNICEM antibiotic-loaded nail products.
  • Stryker: Stryker is both Biocomposites' exclusive distribution partner for Biosteon ACL/rotator cuff screws and a broad orthopaedic and sports medicine incumbent with overlapping sports medicine and orthobiologic product lines.
  • Smith+Nephew: Smith+Nephew is a global medical device company with significant orthopaedic reconstruction, sports medicine, and advanced wound management portfolios, competing in adjacent segments to Biocomposites' bone grafts and infection-management products.
  • Arthrex: Arthrex is a leading privately-held sports medicine and orthopaedic soft tissue repair company; comparable to Biocomposites' Biosteon/Bilok interference screws and suture anchors for ACL and rotator cuff repair.
  • Medtronic: Medtronic's Spine division offers INFUSE (rhBMP-2) and other orthobiologics used in spinal fusion and bone grafting, comparable to Biocomposites' NanoBone, genex, and Allogran-R products serving spine surgeons.

Emerging players

  • Bone Solutions Inc. Bone Solutions Inc. develops Mg-based and calcium-based bone void fillers and orthobiologics (OSTEOAMP, OSTEOMATRIX), an emerging competitor with similar synthetic bone graft technology to Biocomposites' genex and NanoBone lines.
  • OsteoRemedies: OsteoRemedies specializes in antibiotic-loaded calcium sulfate bone void fillers and infection management products in orthopaedics, making it a direct niche competitor to Biocomposites' STIMULAN platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

Biocomposites social profiles

Digital presence

Biocomposites compliance and trust

Trust signal

Compliance3 records

Biocomposites financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biocomposites leadership team

Management profile

Number of profiles

Profiles2 records

Biocomposites subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Biocomposites funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biocomposites M&A and investment

M&A and investment

M&A2 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocomposites

What does Biocomposites do?

Biocomposites engineers, manufactures, and markets calcium compound and specialty polymer medical devices for bone regeneration and infection management. Its portfolio includes absorbable calcium sulfate antibiotic carriers (STIMULAN), acrylic bone cements and preformed antibiotic-loaded spacers (SYNICEM), nanostructured hydroxyapatite bone graft substitutes (NanoBone), biphasic and beta-tricalcium phosphate bone grafts (genex, Allogran-R), and synthetic calcium composite interference screws (Biosteon, Bilok) used in musculoskeletal infection, trauma, spine, foot and ankle, and sports medicine procedures.

Is Biocomposites a public or private company?

Biocomposites is a private company. It is classified as private equity controlled and is currently operating.

When was Biocomposites founded?

Biocomposites was founded in 1993. It employs 251 to 500 people.

Where is Biocomposites based?

Biocomposites is headquartered in Keele, United Kingdom, in the Europe region.

How does Biocomposites make money?

One revenue line is on record: medical Device Sales.

Who are Biocomposites's main competitors?

Direct peers on record are Heraeus Medical and BONESUPPORT Holding AB. Broad incumbents are Zimmer Biomet, DePuy Synthes (Johnson & Johnson), Stryker, Smith+Nephew, Arthrex and Medtronic. Emerging players are Bone Solutions Inc. and OsteoRemedies.

Does Biocomposites have an API?

No public API is recorded for Biocomposites.

What industry is Biocomposites in?

Biocomposites's product category is Orthopaedic and trauma medical devices. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAHAEAA, Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle). Its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingBiocomposites welcomes new clinical pathway for local infection management in severe pressure ulcersBiocomposites welcomed Wounds UK's new clinical pathway for managing osteomyelitis in severe pressure ulcers, including a structured assessment and treatment approach. The guidance also recommends using STIMULAN with antibiotics in selected patients, following a May 2026 expert meeting. Pressure ulcers cost the NHS in England about £3.8 million daily.GlobeNewswireBiocomposites welcomes new clinical pathway for local infection management in severe pressure ulcersBiocomposites welcomed new Wounds UK guidance on osteomyelitis in severe pressure ulcers, including a structured assessment pathway and recommendations for using STIMULAN with antibiotics. The guidance aims to improve early intervention and multidisciplinary care, addressing gaps in clinical evidence and inconsistent practice.BioSpaceBiocomposites to host industry symposium and present new STIMULAN® data at EBJIS-MSIS 2026Biocomposites will host a symposium and present a poster at the EBJIS-MSIS 2026 conference in Porto, Portugal, on September 17-19. The poster shows STIMULAN® calcium sulfate beads loaded with combination antibiotics effectively eradicate S. aureus biofilms on orthopedic implants. The company highlights its MDR certification for mixing the beads with Gram-positive and Gram-negative antibiotics.openPR.comLeading Companies Enhancing Their Presence in the Bone Regeneration Material MarketThe bone regeneration material market is projected to grow to $6.45 billion by 2030, representing a compound annual growth rate of 9.5%, driven by rising demand for regenerative orthopedic treatments, bioprinting advancements, and minimally invasive surgical methods. In June 2023, UK-based medical device manufacturer Biocomposites acquired Artoss GmbH, a Germany-based synthetic bone graft specialist, to expand its portfolio with Artoss's proprietary NanoBone technology through Biocomposites' global distribution network. In May 2023, US-based Royal Biologics launched Bio-Reign 3D, a novel synthetic bone graft substitute featuring a hyper-crosslinked carbohydrate polymer matrix designed for orthopedic use with radiolucent imaging properties.InsidermediaLife sciences firm to expand operation after landing government fundingBiocomposites, a life sciences manufacturing company based at Keele's Science and Innovation Park, has secured £1.7m from the UK government's Life Sciences Innovative Manufacturing Fund to expand its headquarters and manufacturing operations. The funding will specifically support increased production of the company's flagship STIMULAN product using innovative ceramic-based materials. The expansion aims to help Biocomposites meet growing customer demand and support its ambitious growth plans at its primary manufacturing site.BBCKeele-based medical tech firm gets £1.7m grant for expansionBiocomposites, a medical tech firm based at Keele University's Science and Innovation Park, has received a £1.7m government grant to expand its facilities and increase production of its flagship product Stimulan, a ceramic-based material used to treat infections. The funding will enable the company to invest in cutting-edge manufacturing technology and improve its working environment to keep pace with customer demand and support ambitious growth plans. The company has operated at the park since 2004 and has become an integral part of the north Staffordshire community, hiring university students and collaborating with researchers.GlobeNewswireBiocomposites to launch SYNICEM™ bone cement in UK to ease supply crisisBiocomposites is launching its SYNICEM bone cement products in the UK immediately to address an NHS supply crisis. The company is doubling production to one million packs annually, and the cements are CE marked and approved for use in the UK.GlobeNewswireBiocomposites to launch SYNICEM™ bone cement in UK to ease supply crisisBiocomposites, a UK-based medical devices company, announced the immediate UK launch of its SYNICEM™ bone cement products to address an acute NHS supply crisis that threatens to delay thousands of orthopaedic operations including hip and knee replacements. The company is doubling its global production capacity to one million packs a year, with the launch being brought forward from its originally planned timeline. SYNICEM™ products have been manufactured by Biocomposites' subsidiary Synimed for over 25 years and are already approved for use in the UK.BioSpaceBiocomposites to launch SYNICEM™ bone cement in UK to ease supply crisisBiocomposites has announced the immediate UK launch of its SYNICEM™ bone cement products, bringing forward the planned rollout to address an acute NHS supply crisis threatening to delay thousands of orthopaedic operations. The British medical devices company is simultaneously doubling its global production capacity to one million packs per year, primarily to meet UK demand. The company stated these measures will go a long way toward meeting NHS bone cement demand and minimising delays to hip and knee replacement procedures.Business InsiderBiocomposites to launch SYNICEM™ bone cement in UK to ease supply crisisBiocomposites, a UK-based medical devices company, has launched its SYNICEM™ bone cement products in the UK with immediate effect to address an acute NHS supply crisis affecting orthopaedic operations. The company is doubling its global production capacity to one million packs annually to meet NHS demand and minimize delays to procedures such as hip and knee replacements. The SYNICEM™ products, which have been manufactured for over 25 years, are already CE marked and used in over 100 countries worldwide.